Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence. (PubMed, Support Care Cancer) - Oct 7, 2026 - "In routine practice, approximately one in five adults with DLBCL receiving first-line R-CHOP-based therapy develops FN-an incidence at, rather than below, the conventional 20% threshold for primary G-CSF prophylaxis. Trial-derived estimates should not be assumed to represent this burden."
Clinical • Journal • Retrospective data • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin's Lymphoma • Oncology
|
|
Alexander Reyes; Jamiel Reyes
|